FDMT — 4D Molecular Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1650648 ·
Last close
$12.70
Market Cap
$701.60M
52W High
$16.93
52W Low
$6.96
ADV30
990,849
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,781,000 | — | -77,025,000 | -72,936,000 | 492,615,000 | 70,372,000 | 84,956,000 |
| Mar 2026 | 3,047,000 | — | -73,620,000 | -68,760,000 | 512,905,000 | 72,488,000 | 61,069,000 |
| Dec 2025 | 85,090,000 | — | 14,715,000 | 19,397,000 | 566,711,000 | 60,241,000 | 61,047,000 |
| Sep 2025 | 90,000 | — | -61,185,000 | -56,876,000 | 423,982,000 | 48,555,000 | 54,999,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-129,449,000
Investing CF
$-56,033,000
Financing CF
$124,444,000
CapEx
$-1,646,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.86
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-785,064,000
Inventory
—
Receivables
—
ST Investments
$318,404,000
EBIT TTM
$-179,546,000
Pretax Income TTM
$-160,897,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$92,008,000
EBITDA
$-188,890,000
Free Cash Flow
$-90,773,504
Enterprise Value
$405,449,248
Total Cash
$361,334,016
Total Debt
$39,217,000
Shares Out
55,244,211
Trailing EPS
$-2.63
Book Value
$7.38
ROE
-43.2%
ROA
-25.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 85,209,000 | -159,547,000 | -140,109,000 | 566,711,000 | 61,047,000 | 505,664,000 | -109,082,000 |
| Dec 2024 | 37,000 | -187,841,000 | -160,868,000 | 560,384,000 | 49,778,000 | 510,606,000 | -134,585,000 |
| Dec 2023 | 20,723,000 | -112,867,000 | -100,837,000 | 339,891,000 | 32,062,000 | 307,829,000 | -75,792,000 |
| Dec 2022 | 3,129,000 | -110,032,000 | -107,494,000 | 261,846,000 | 30,509,000 | 231,337,000 | -86,685,000 |
TTM Snapshot
Revenues TTM
$88,242,000
NetIncome TTM
$-160,897,000
OpCashFlow TTM
—
Assets (Latest)
$512,905,000
Forward EPS
$-4.08
Max Pain — expiry 2026-10-16
max pain strike: $9.00 · spot: $13.33 · call oi: 3,488 · put oi: 97Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AURA | Aura Biosciences, Inc. | $674.60M | $6.51 | — |
| SLDB | Solid Biosciences Inc. | $731.28M | $6.82 | — |
| CADL | Candel Therapeutics, Inc. | $739.17M | $9.66 | — |
| ATTO | Attovia Therapeutics, Inc. | $744.57M | $16.31 | — |
| PRME | Prime Medicine, Inc. | $649.33M | $3.58 | — |
News headlines (Yahoo Finance, 1h cache)
This is the top biotech stock pick from B Riley Securities
2026-09-29 21:24 · Yahoo
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
2026-09-28 17:15 · Yahoo
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
2026-09-28 12:00 · Yahoo
4DMT Announces New Employment Inducement Grants
2026-09-11 20:05 · Yahoo
4DMT to Participate in Upcoming Investor Conferences
2026-08-25 12:00 · Yahoo
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
2026-08-17 23:51 · Yahoo
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 22:05 · Yahoo
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
2026-06-29 12:00 · Yahoo
4DMT to Host Investor Day on October 21, 2026
2026-10-05 12:00 · Yahoo
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
2026-08-13 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.